Canaccord analyst Kyle Rose maintains his Buy rating on Sientra (SIEN) following the release of briefing documents ahead of next week's FDA panel meeting to review a range of topics related to the long-term benefits and risks of breast implants, stating that the documents appear to be in-line with expectations and do not appear to raise any materially new or concerning questions or data. However, given the warning letters sent this week to Sientra and J&J's (JNJ) Mentor unit, Rose said he expects the FDA to "take a strong tone" during the panel about the responsibility to support the collection and analysis of relevant safety and efficacy clinical data. Other makers of breast implants include Allergan (AGN) and Establishment Labs (ESTA).